<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="http://creativecommons.org/licenses/by-nc/4.0medi-99-e20583.pdf Abstract Abstract To observe the efficacy of telbivudine in" exact="chronic hepatitis" post="B (CHB) women with high viral load during pregnancy"/>
 <result pre="Abstract Abstract To observe the efficacy of telbivudine in chronic" exact="hepatitis" post="B (CHB) women with high viral load during pregnancy"/>
 <result pre="of telbivudine in chronic hepatitis B (CHB) women with high" exact="viral" post="load during pregnancy and the long-term effects on intelligence,"/>
 <result pre="effects on intelligence, growth, and development of the newborns. A" exact="total" post="of 87 patients were included. Forty-two patients received telbivudine"/>
 <result pre="treatment initiated from 12 weeks after gestation until the 12th" exact="postpartum" post="week. Forty-five patients were untreated according to principle of"/>
 <result pre="to principle of informed consent. All infants received injection of" exact="hepatitis" post="B immune globulin (HBIG; 200 IU) and were vaccinated"/>
 <result pre="they were 6 years old. Data including serum HBV DNA" exact="viral" post="load, Apgar score, and scores of Wechsler preschool intelligence"/>
 <result pre="12th week after delivery in the telbivudine group were significantly" exact="lower" post="than those of patients without telbivudine (P &amp;lt; .01). The serum"/>
 <result pre="neonates 7 months of age was 0%, which was significantly" exact="lower" post="than that in control group (11.11%) (P &amp;lt; .05). No statistical"/>
 <result pre="2 groups regarding maternal cesarean section rate, adverse pregnancy rate," exact="postpartum" post="bleeding rate, neonatal body mass, Apgar score, neonatal malformation"/>
 <result pre="groups regarding maternal cesarean section rate, adverse pregnancy rate, postpartum" exact="bleeding" post="rate, neonatal body mass, Apgar score, neonatal malformation incidence,"/>
 <result pre="maternal cesarean section rate, adverse pregnancy rate, postpartum bleeding rate," exact="neonatal" post="body mass, Apgar score, neonatal malformation incidence, or intelligence"/>
 <result pre="pregnancy rate, postpartum bleeding rate, neonatal body mass, Apgar score," exact="neonatal" post="malformation incidence, or intelligence development of newborn. Telbivudine is"/>
 <result pre="intelligence development of newborn. Telbivudine is effective to reduce the" exact="viral" post="load in CHB mothers with high viral load and"/>
 <result pre="to reduce the viral load in CHB mothers with high" exact="viral" post="load and could lower the perinatal transmission rate. Both"/>
 <result pre="load in CHB mothers with high viral load and could" exact="lower" post="the perinatal transmission rate. Both mental and physical development"/>
 <result pre="perinatal period were similar to those without telbivudine exposure. Keywords" exact="Hepatitis" post="B virus long-term efficacy and safety mother-neonatal transmission pregnancy"/>
 <result pre="long-term efficacy and safety mother-neonatal transmission pregnancy telbivudine 1 Introduction" exact="Chronic" post="hepatitis B virus (CHB) infection remains to be a"/>
 <result pre="efficacy and safety mother-neonatal transmission pregnancy telbivudine 1 Introduction Chronic" exact="hepatitis" post="B virus (CHB) infection remains to be a global"/>
 <result pre="transmission pregnancy telbivudine 1 Introduction Chronic hepatitis B virus (CHB)" exact="infection" post="remains to be a global health problem.[1–5] Vertical transmission"/>
 <result pre="remains to be a global health problem.[1–5] Vertical transmission of" exact="Hepatitis" post="B Virus (HBV) from mothers to their infants at"/>
 <result pre="a major contributor to HBV epidemics.[6,7] The combination of both" exact="hepatitis" post="B immunoglobulin (HBIg) and HBV vaccine in newborn was"/>
 <result pre="rate still needs improvement, especially in CHB mothers with high" exact="viral" post="load (such as serum HBV DNA &amp;gt; 106–7 IU/mL). Thus, perinatal application"/>
 <result pre="profile of long-term LdT duration in pregnant women with high" exact="viral" post="load and potential effects on mental and physical development"/>
 <result pre="was administrated from 12 weeks after gestation to the 12th" exact="postpartum" post="week. All patients had HBV DNA levels great than"/>
 <result pre="patients had HBV DNA levels great than 107 IU/mL. Coinfection with" exact="hepatitis" post="C virus, hepatitis D virus, hepatitis A virus, hepatitis"/>
 <result pre="DNA levels great than 107 IU/mL. Coinfection with hepatitis C virus," exact="hepatitis" post="D virus, hepatitis A virus, hepatitis E virus, human"/>
 <result pre="than 107 IU/mL. Coinfection with hepatitis C virus, hepatitis D virus," exact="hepatitis" post="A virus, hepatitis E virus, human immunodeficiency virus, concurrently"/>
 <result pre="with hepatitis C virus, hepatitis D virus, hepatitis A virus," exact="hepatitis" post="E virus, human immunodeficiency virus, concurrently being confirmed with"/>
 <result pre="hepatitis D virus, hepatitis A virus, hepatitis E virus, human" exact="immunodeficiency" post="virus, concurrently being confirmed with other liver diseases (drug-induced"/>
 <result pre="being confirmed with other liver diseases (drug-induced hepatitis, nonalcoholic steatohepatitis," exact="autoimmune" post="hepatitis, ntrahepatic cholestasis of pregnancy, etc.) or having signs"/>
 <result pre="other liver diseases (drug-induced hepatitis, nonalcoholic steatohepatitis, autoimmune hepatitis, ntrahepatic" exact="cholestasis" post="of pregnancy, etc.) or having signs of fetal dysplasia"/>
 <result pre="ntrahepatic cholestasis of pregnancy, etc.) or having signs of fetal" exact="dysplasia" post="were excluded. Informed consents were received from all the"/>
 <result pre="were tested at the time of delivery, 1st and 7th" exact="postpartum" post="months. The infants’ respiratory rate, weight, length, breast feeding"/>
 <result pre="time of delivery, 1st and 7th postpartum months. The infants’" exact="respiratory" post="rate, weight, length, breast feeding status, and intelligence quotient"/>
 <result pre="and 7th postpartum months. The infants’ respiratory rate, weight, length," exact="breast" post="feeding status, and intelligence quotient were evaluated at each"/>
 <result pre="Kehua Bio-engineering Co, Ltd, Shanghai, China),[13,14] serum markers of HBV" exact="infection" post="including serum HBeAg, HBsAg, and HBsAb were determined using"/>
 <result pre="enzyme-linked immunosorbent assay (Shanghai Kehua Bio-engineering Co Ltd). Laboratory examination" exact="of liver" post="and kidney function was performed with an automated bioanalyzer."/>
 <result pre="determined by both serum HBV DNA and HBsAg in the" exact="peripheral" post="blood of infants at month 7, according to international"/>
 <result pre="0.05. 3 Results 3.1 Patient disposition and baseline characteristics A" exact="total" post="87 mothers were enrolled: 42 in the LdT-treated group"/>
 <result pre="serum HBV DNA levels in the LdT-treated group were significantly" exact="lower" post="than that in control group (Table 2). The mean"/>
 <result pre="DNA levels of control group remained high. At the 12th" exact="postpartum" post="week, the average serum HBV DNA levels in the"/>
 <result pre="DNA levels in the LdT group were 3.10 ± 0.34 log10 copies/mL, much" exact="lower" post="than that in control groups (P &amp;lt; .001). Table 2 Dynamic"/>
 <result pre="showed that perinatal LdT application in pregnant women with high" exact="viral" post="load was effective and safe to reduce the transmission"/>
 <result pre="higher than 108 copies/mL.[17] Recent studies had shown that maternal serum" exact="viral" post="load in the third trimester of gestation was correlated"/>
 <result pre="in the third trimester of gestation was correlated with HBV" exact="infection" post="of their infants and MTCT could not be prevented"/>
 <result pre="indicated that telbivudine treatment during pregnancy in women with high" exact="viral" post="load could effectively block MTCT.[20,21] Moreover, our study showed"/>
 <result pre="know the exact time of infection, neither their family history," exact="disease" post="duration was not included in our study. 5 Conclusion"/>
 <result pre="anhua hao, lin zhou. Abbreviations: ADV = adefovir, CHB =" exact="chronic hepatitis" post="B, CI = confidence interval, ETV = entecavir, HBsAg"/>
 <result pre="hao, lin zhou. Abbreviations: ADV = adefovir, CHB = chronic" exact="hepatitis" post="B, CI = confidence interval, ETV = entecavir, HBsAg"/>
 <result pre="B, CI = confidence interval, ETV = entecavir, HBsAg =" exact="hepatitis" post="B surface antigen, HBV DNA = hepatitis B virus"/>
 <result pre="entecavir, HBsAg = hepatitis B surface antigen, HBV DNA =" exact="hepatitis" post="B virus deoxyribonucleic acid, LAM = lamivudine, PCR ="/>
 <result pre="[1]ZhengZLiaoWLiuLet al.Effect of nucleos(t)ide analogue on serum HBsAg level in" exact="chronic hepatitis" post="B patients: a 3-years study. Biomed Pharmacother2020;122:109698.31918272 [2]ZhengCYanHZengJet al.Comparison"/>
 <result pre="al.Effect of nucleos(t)ide analogue on serum HBsAg level in chronic" exact="hepatitis" post="B patients: a 3-years study. Biomed Pharmacother2020;122:109698.31918272 [2]ZhengCYanHZengJet al.Comparison"/>
 <result pre="novo pegylated interferon plus tenofovir combination therapy in patients with" exact="chronic hepatitis" post="B. Infect Drug Resist2019;12:845–54.31114265 [3]SarinSKKumarMLauGKet al.Asian-Pacific clinical practice guidelines"/>
 <result pre="pegylated interferon plus tenofovir combination therapy in patients with chronic" exact="hepatitis" post="B. Infect Drug Resist2019;12:845–54.31114265 [3]SarinSKKumarMLauGKet al.Asian-Pacific clinical practice guidelines"/>
 <result pre="Resist2019;12:845–54.31114265 [3]SarinSKKumarMLauGKet al.Asian-Pacific clinical practice guidelines on the management of" exact="hepatitis" post="B: a 2015 update. Hepatol Int2016;10:1–98. [4]collab: European Association"/>
 <result pre="Liver. EASL 2017 Clinical Practice Guidelines on the management of" exact="hepatitis" post="B virus infection. J Hepatol2017;67:370–98.28427875 [5]AnaedobeCGFowotadeAOmoruyiCEet al.Prevalence, sociodemographic features"/>
 <result pre="2017 Clinical Practice Guidelines on the management of hepatitis B" exact="virus infection." post="J Hepatol2017;67:370–98.28427875 [5]AnaedobeCGFowotadeAOmoruyiCEet al.Prevalence, sociodemographic features and risk factors"/>
 <result pre="J Hepatol2017;67:370–98.28427875 [5]AnaedobeCGFowotadeAOmoruyiCEet al.Prevalence, sociodemographic features and risk factors of" exact="Hepatitis" post="B virus infection among pregnant women in Southwestern Nigeria."/>
 <result pre="[5]AnaedobeCGFowotadeAOmoruyiCEet al.Prevalence, sociodemographic features and risk factors of Hepatitis B" exact="virus infection" post="among pregnant women in Southwestern Nigeria. Pan Afr Med"/>
 <result pre="al.Prevalence, sociodemographic features and risk factors of Hepatitis B virus" exact="infection" post="among pregnant women in Southwestern Nigeria. Pan Afr Med"/>
 <result pre="Med J2015;20:406.26301010 [6]GoyalAMurrayJMThe impact of vaccination and antiviral therapy on" exact="hepatitis" post="B and hepatitis D epidemiology. PLos One2014;9:e110143.25313681 [7]YiWLiMHXieYet al.Prospective"/>
 <result pre="impact of vaccination and antiviral therapy on hepatitis B and" exact="hepatitis" post="D epidemiology. PLos One2014;9:e110143.25313681 [7]YiWLiMHXieYet al.Prospective cohort study on"/>
 <result pre="of telbivudine used throughout pregnancy in blocking mother-to-child transmission of" exact="hepatitis" post="B virus. J Viral Hepat2017;24: suppl 1: 49–56.29082650 [8]LiJChangMSTranTTet"/>
 <result pre="pregnancy in blocking mother-to-child transmission of hepatitis B virus. J" exact="Viral" post="Hepat2017;24: suppl 1: 49–56.29082650 [8]LiJChangMSTranTTet al.Management of chronic Hepatitis"/>
 <result pre="virus. J Viral Hepat2017;24: suppl 1: 49–56.29082650 [8]LiJChangMSTranTTet al.Management of" exact="chronic" post="Hepatitis B in pregnancy. J Clin Gastroenterol2017;51:789–95.28816860 [9]AbaraWEChaSMalikTet al.Prenatal"/>
 <result pre="J Viral Hepat2017;24: suppl 1: 49–56.29082650 [8]LiJChangMSTranTTet al.Management of chronic" exact="Hepatitis" post="B in pregnancy. J Clin Gastroenterol2017;51:789–95.28816860 [9]AbaraWEChaSMalikTet al.Prenatal screening"/>
 <result pre="J Clin Gastroenterol2017;51:789–95.28816860 [9]AbaraWEChaSMalikTet al.Prenatal screening for and prevalence of" exact="Hepatitis" post="B surface antigen in pregnant women and prevention of"/>
 <result pre="of transmission to infants born to infected mothers-Guam, 2014. J" exact="Pediatric" post="Infect Dis Soc2018;7:290–5.28992071 [10]LimSSLiaoHTTsaiCYTelbivudine associated mitochondrial myopathy. Liver Int2018;38:1139.29570939"/>
 <result pre="infected mothers-Guam, 2014. J Pediatric Infect Dis Soc2018;7:290–5.28992071 [10]LimSSLiaoHTTsaiCYTelbivudine associated" exact="mitochondrial myopathy." post="Liver Int2018;38:1139.29570939 [11]ZhangHPanCQPangQet al.Telbivudine or lamivudine use in late"/>
 <result pre="mitochondrial myopathy. Liver Int2018;38:1139.29570939 [11]ZhangHPanCQPangQet al.Telbivudine or lamivudine use in" exact="late pregnancy" post="safely reduces perinatal transmission of hepatitis B virus in"/>
 <result pre="lamivudine use in late pregnancy safely reduces perinatal transmission of" exact="hepatitis" post="B virus in real-life practice. Hepatology2014;60:468–76.25187919 [12]HuYXuCXuBet al.Safety and"/>
 <result pre="real-life practice. Hepatology2014;60:468–76.25187919 [12]HuYXuCXuBet al.Safety and efficacy of telbivudine in" exact="late pregnancy" post="to prevent mother-to-child transmission of hepatitis B virus: a"/>
 <result pre="of telbivudine in late pregnancy to prevent mother-to-child transmission of" exact="hepatitis" post="B virus: a multicenter prospective cohort study. J Viral"/>
 <result pre="of hepatitis B virus: a multicenter prospective cohort study. J" exact="Viral" post="Hepat2018;25:429–37.29193547 [13]CaiSHLvFFZhangYHet al.Dynamic comparison between Daan real-time PCR and"/>
 <result pre="BMC Infect Dis2014;14:85.24528480 [14]XueXCaiSComment on &quot;Assessment of Liver Stiffness in" exact="Pediatric" post="Fontan Patients Using Transient Elastography�?. Can J Gastroenterol Hepatol2016;2016:9343960.28025635"/>
 <result pre="on &quot;Assessment of Liver Stiffness in Pediatric Fontan Patients Using" exact="Transient" post="Elastography�?. Can J Gastroenterol Hepatol2016;2016:9343960.28025635 [15]HanGRCaoMKZhaoWet al.A prospective and"/>
 <result pre="telbivudine in pregnancy for the prevention of perinatal transmission of" exact="hepatitis" post="B virus infection. J Hepatol2011;55:1215–21.21703206 [16]HanGRJiangHXYueXet al.Efficacy and safety"/>
 <result pre="pregnancy for the prevention of perinatal transmission of hepatitis B" exact="virus infection." post="J Hepatol2011;55:1215–21.21703206 [16]HanGRJiangHXYueXet al.Efficacy and safety of telbivudine treatment:"/>
 <result pre="in pregnant women for the prevention of perinatal transmission of" exact="hepatitis" post="B virus infection. J Viral Hepat2015;22:754–62.25641421 [17]WuQHuangHSunXet al.Telbivudine prevents"/>
 <result pre="women for the prevention of perinatal transmission of hepatitis B" exact="virus infection." post="J Viral Hepat2015;22:754–62.25641421 [17]WuQHuangHSunXet al.Telbivudine prevents vertical transmission of"/>
 <result pre="prevention of perinatal transmission of hepatitis B virus infection. J" exact="Viral" post="Hepat2015;22:754–62.25641421 [17]WuQHuangHSunXet al.Telbivudine prevents vertical transmission of hepatitis B"/>
 <result pre="infection. J Viral Hepat2015;22:754–62.25641421 [17]WuQHuangHSunXet al.Telbivudine prevents vertical transmission of" exact="hepatitis" post="B virus from women with high viral loads: a"/>
 <result pre="vertical transmission of hepatitis B virus from women with high" exact="viral" post="loads: a prospective long-term study. Clin Gastroenterol Hepatol2015;13:1170–6.25251571 [18]TanZYinYZhouJet"/>
 <result pre="prospective long-term study. Clin Gastroenterol Hepatol2015;13:1170–6.25251571 [18]TanZYinYZhouJet al.Telbivudine treatment of" exact="hepatitis" post="B virus-infected pregnant women at different gestational stages for"/>
 <result pre="al.Telbivudine treatment of hepatitis B virus-infected pregnant women at different" exact="gestational" post="stages for the prevention of mother-to-child transmission: Outcomes of"/>
 <result pre="telbivudine treatment during pregnancy. Medicine (Baltimore)2016;95:e4847.27749537 [19]BrownRJMcMahonBJLokASet al.Antiviral therapy in" exact="chronic hepatitis" post="B viral infection during pregnancy: a systematic review and"/>
 <result pre="treatment during pregnancy. Medicine (Baltimore)2016;95:e4847.27749537 [19]BrownRJMcMahonBJLokASet al.Antiviral therapy in chronic" exact="hepatitis" post="B viral infection during pregnancy: a systematic review and"/>
 <result pre="pregnancy. Medicine (Baltimore)2016;95:e4847.27749537 [19]BrownRJMcMahonBJLokASet al.Antiviral therapy in chronic hepatitis B" exact="viral infection" post="during pregnancy: a systematic review and meta-analysis. Hepatology2016;63:319–33.26565396 [20]SunWZhaoSMaLet"/>
 <result pre="Medicine (Baltimore)2016;95:e4847.27749537 [19]BrownRJMcMahonBJLokASet al.Antiviral therapy in chronic hepatitis B viral" exact="infection" post="during pregnancy: a systematic review and meta-analysis. Hepatology2016;63:319–33.26565396 [20]SunWZhaoSMaLet"/>
</results>
